Smith & Nephew, shares trade near 1,118 pence in London
23.06.2026 - 20:22:23 | ad-hoc-news.deBy Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 18:21.
Smith & Nephew (GB0009223206) traded at 1,118.00 GBX in London at 19:00 on 23 June 2026. Investing.com shows a Buy consensus from 17 analysts, with an average 12-month target of 1,410.57 GBP. Investing.com consensus estimate page
Consensus stays supportive
The analyst mix is split, but the balance leans constructive. Investing.com lists 7 Buy ratings, 10 Hold ratings and no Sell rating on the current consensus page.
MarketBeat's London quote page puts Smith & Nephew's market value at 12.21 billion pounds and its dividend yield at 3.66 percent. The same page shows the shares at 1,113.50 GBX as of 22 June 2026. MarketBeat London quote page
August sits on the calendar
The next dated company event is the second quarter and first-half 2026 release on 4 August 2026, according to Smith & Nephew's first-quarter trading update. That update also scheduled an analyst conference call for 6 May 2026 and outlined a 500 million dollar share buyback. Smith & Nephew first-quarter trading update
All news and analysis on Smith & Nephew shares
The London-listed medtech group combines analyst consensus, a scheduled August update and a current London quote in one place.
The business behind the stock
Smith & Nephew sells orthopedic reconstruction, sports medicine and wound care products. The company describes itself as a medical technology group with international operations.
London quote at 19:00
The Smith & Nephew shares (GB0009223206) trade on 23 June 2026, 19:00 on the London market at 1,118.00 GBX.
Key data on Smith & Nephew shares
- Company: Smith & Nephew plc
- ISIN: GB0009223206
- Ticker: SN
- Trading venue: London
- Price (as of 2026-06-23, 19:00): 1,118.00 GBX
- Market cap: £12.21 billion (as of 2026-06-22)
- Sector / industry: Health Care Equipment & Supplies
- Index membership: FTSE 100
- Next earnings date: 2026-08-04
Disclaimer: This article is for information only and does not constitute investment advice.
